Gastric emptying-promoting composition
AssigneeAmano Pharmaceutical Co., Ltd.
InventorTakaharu Kondo
Life of this patent
Estimating the term…
Abstract
Compositions having an effect of promoting gastric emptying. These compositions comprise a lipase which was found to have an effect of promoting gastric emptying together with lipase activity-free ingredient(s) acting on the digestive tracts such as a prokinetic, a histamine H2 receptor antagonist, a proton pump inhibitor and/or a stomachic ingredient. They are efficaciously employed as medicaments for ameliorating or treating chronic gastrointestinal symptoms such as sinking feelings, heartburn and heaviness in the stomach, i.e., complaints about the digestive tracts.
Claims13
A gastric emptying-promoting composition consisting essentially of, as an active ingredient, lipase active at gastric pH values so as to digest lipids, wherein said lipase is derived from a microorganism, and is selected from the group consisting of Lipase AP4, Lipase AP6, and Lipase AP12 and at least one substance selected from the group consisting of prokinetics, histamine H2 receptor antagonists, proton pump inhibitors and stomachic crude drugs.
A method for promoting gastric emptying in a subject who needs gastric emptying promotion on the basis of gastric emptying time measured by the electrical impedance tomography (EIT) with the use of an APT system DAS-01P developed in Sheffield University, which comprises orally administering together with or after taking a lipid containing food, to said subject:
- a lipase active in the stomach to digest lipids, wherein said lipase is derived from a microorganism, and is selected from the group consisting of Lipase AP4, Lipase AP6, and Lipase AP12, said lipase being administered in an amount effective for promoting gastric emptying;
- and a lipid containing food.
A method for promoting gastric emptying in a subject who needs gastric emptying promotion on the basis of gastric emptying time measured by the electrical impedance tomography (EIT) with the use of an APT system DAS-01P developed in Sheffield University, which comprises orally administering together with or after taking a lipid containing food, to said subject:
- a lipase active in the stomach to digest lipids, wherein said lipase is derived from a microorganism, and is selected from the group consisting of Lipase AP4, Lipase AP6, and Lipase AP12, said lipase being administered in an amount effective for promoting gastric emptying;
- and the lipid containing food, and which further comprises administering at least one substance selected from the group consisting of prokinetics, histamine H2 receptor antagonists, proton pump inhibitors and stomachic crude drugs.
A gastric emptying-promoting composition, which comprises a single dose of lipase having an activity of 300U or more in terms of fat-digestibility of fat containing food, and which consists essentially of, as an active ingredient, lipase active at gastric pH values so as to digest lipids, wherein said lipase is derived from a microorganism, and is selected from the group consisting of Lipase AP4, Lipase AP6, and Lipase AP12, and at least one substance selected from the group consisting of prokinetics, histamine H2 receptor antagonists, proton pump inhibitors and stomachic crude drugs.
A gastric emptying-promoting composition, which comprises a single dose of lipase having an activity of 300U or more and 240 mg or less, and which consists essentially of, as an active ingredient, lipase active at gastric pH values so as to digest lipids, wherein said lipase is derived from a microorganism, and is selected from the group consisting of Lipase AP4, Lipase AP6, and Lipase AP12, and at least one substance selected from the group consisting of prokinetics, histamine H2 receptor antagonists proton pump inhibitors and stomachic crude drugs.
A method for promoting gastric emptying in a subject who needs gastric emptying promotion on the basis of gastric emptying time measured by the electrical impedance tomography (EIT) with the use of an APT system DAS-01P developed in Sheffield University, which comprises orally administering together with or after taking a lipid containing food, to said subject:
- a lipase active in the stomach to digest lipids, wherein said lipase is derived from a microorganism, and is selected from the group consisting of Lipase AP4, Lipase AP6, and Lipase AP12, said lipase being administered in a dose having an activity of 300U or more and 240 mg or less;
- and the lipid containing food.
Dependencies are inferred from the claim text.